TPMT and systemic sclerosis: Our conclusion that all patients with SSc were carriers of TPMT*3A instead of *3B or *3C is aligned with the fact that no severe side effects (e.g., myelosuppresion or neutropenia associated with thiopurine administration) were reported following the treatment with AZA.